Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VcR-CVAD with Rituximab Maintenance for Untreated Mantle Cell Lymphoma
NCT00433537Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2007
- Primary completion
- Jun 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in mantle cell lymphoma (MCL), sponsored by National Cancer Institute. Started May 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00433537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00433537.